Biotech Event Tracker

274 events

Date	Symbol	Description	Type	Disease	Designation	Success Rating
H2 2018	MACK	Merrimack Pharmaceuticals (MACK) Phase 2 Results of Seribantumab (MM-121) for Non-Small Cell Lung Cancer	Phase 2 Results	Oncology	Fast Track
H2 2016	ARRY	Array BioPharma (ARRY) Phase 3 Results of Selumetinib for KRAS-mutant Non-Small Cell Lung Cancer	Phase 3 Results	Oncology	Orphan Drug
Q4 2016	KPTI	Karyopharm (KPTI) Phase 2/3 Results of Selinexor for Multiple Myeloma	Phase 2/3 Results	Oncology	Orphan Drug
Q4 2016	CYCC	Cyclacel Pharmaceuticals (CYCC) Phase 3 Results of Sapacitabine for Myeloid Leukemia	Phase 3 Results	Oncology	Orphan Drug
H2 2016	SAGE	Sage Therapeutics (SAGE) Phase 3 Results of SAGE-547 for Super-Refractory Status Epilepticus	Phase 3 Results	Respiratory	Fast Track, Orphan Drug
H1 2017	CLVS	Clovis Oncology (CLVS) Phase 3 Results of Rucaparib for Ovarian Cancer	Phase 3 Results	Oncology	Breakthrough Therapy
Q3 2016	NVAX	Novavax (NVAX) Phase 3 Pivotal Results of RSV F Vaccine for Respiratory Syncytial Virus	Phase 3 Results	Infectious Disease	Fast Track
H2 2016	NVAX	Novavax (NVAX) Phase 2 Rollover Trial Results of RSV F Vaccine for Respiratory Syncytial Virus	Phase 2 Results	Infectious Disease	Fast Track
H2 2016	NVAX	Novavax (NVAX) Phase 2 Rollover Trial Results of RSV F Vaccine for Respiratory Syncytial Virus	Phase 2 Results	Infectious Disease	Fast Track
Q1 2017	RTTR	Ritter Pharmaceuticals (RTTR) Phase 2B/3 Results of RP-G28 for Lactose Intolerance	Phase 2/3 Results	Other	None